MDL | - |
---|---|
Molecular Weight | 460.32 |
Molecular Formula | C21H14F6O5 |
SMILES | O=C(OC(C(F)(F)F)(C)C(F)(F)F)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1 |
VKOR [1]
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00691470 | ARYx Therapeutics |
Atrial Fibrillation|Atrial Flutter|Venous Thromboembolic Disease|Myocardial Infarction|Cardiomyopathy
|
May 2008 | Phase 2|Phase 3 |
NCT02522221 | Espero Biopharma |
Thromboembolism|Thrombosis
|
June 1, 2018 | Phase 3 |
NCT04627116 | Lee´s Pharmaceutical Limited |
Healthy Chinese Volunteers
|
April 19, 2020 | Phase 1 |
NCT00431782 | ARYx Therapeutics |
Atrial Fibrillation
|
December 2006 | Phase 2 |
NCT03652779 | Lee´s Pharmaceutical Limited |
Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin
|
June 22, 2018 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 250 mg/mL ( 543.10 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.1724 mL | 10.8620 mL | 21.7240 mL |
5 mM | 0.4345 mL | 2.1724 mL | 4.3448 mL |
10 mM | 0.2172 mL | 1.0862 mL | 2.1724 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.52 mM); Clear solution